VISTERRA, INC.

CAMBRIDGE, MA · Founded 2007 · Biotech · Private

Monoclonal antibodies and scFv antibody fragments targeting specific RNA modifications

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Founded
2007
Latest Form D
$12.9M, May 2012
Total capital
$22.3M
Federal grants
$150K
1 award · 2016
Rank in peer group#4 of 1449
Private capital raised
$22.1M
3 Form D · last May 2012
173 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
19
21 pending · first 2023
Rank in peer group#51 of 1449

Capital timeline

20092010201120122013201420152016FEDERAL ↑EQUITY ↓Cumulative $22.3M$150K1st Form D$3.2M2nd Form D$6M3rd Form D$12.9M
2009201120132015FEDERAL ↑EQUITY ↓Cumulative $22.3M$150K3rd Form D$12.9M

Latest events

  • Federal grantHealth and Human S · Phase I · A Library of Immunoaffinity Reagents for RNA modifications$150K
  • Private capital raisedForm D · SEC · 3rd filing$12.9M
  • Private capital raisedForm D · SEC · 2nd filing$6M
  • Private capital raisedForm D · SEC · 1st filing$3.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Federal grants#4 · top 1%
  • Granted patents#51 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Alan CraneDirectorNamed in SEC Form D filings
  • Brian J.G. Pereira, M.D.Executive Officer, DirectorNamed in SEC Form D filings
  • David J.G. ArkowitzExecutive OfficerNamed in SEC Form D filings
  • Edward KaniaDirectorNamed in SEC Form D filings
  • Kevin BittermanDirectorNamed in SEC Form D filings
  • Ram SasisekharanDirectorNamed in SEC Form D filings
Show all 7 people
  • Steven BruggerExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 19 granted of 40
  • PendingAntibody Molecules To C5AR1 And Uses ThereofUSPTOApplication 19409656
  • PendingAntibody Molecules To April And Uses ThereofUSPTOApplication 18899795
  • PendingHumanized Antibody Molecules To CD138 And Uses ThereofUSPTOApplication 19214961
Show all 40 patent records
  • Cyrus Biotechnology, Inc.Similar federal contract value in Biotech · null in contracts
  • POLARITYTE, INC.Similar federal contract value in Biotech · null in contracts
  • Grace Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Noema PharmaSimilar federal contract value in Biotech · null in contracts
  • Cerium Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
  • KallyopeSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .